Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.

摘要: Abstract Objective To focus on the potential beneficial effects of pleiotropic dipeptidyl peptidase-4 inhibitors (DPP4is) attenuating progression diabetic kidney disease in reducing long-term effect acute injury (AKI) to chronic (CKD) transition. Patients and Methods Data from National Health Insurance Research Database January 1, 1999, July 31, 2011, were analyzed, patients with diabetes weaning dialysis-requiring AKI identified. Cox proportional hazards models inverse-weighted estimates probability treatment used adjust for selection bias. The outcomes incident end-stage renal (ESRD) mortality, major adverse cardiovascular events, hospitalized heart failure. Results Of a total 6165 identified, 5635 (91.4%) DPP4i nonusers 530 (8.6%) users. Compared nonusers, users had lower risk ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) all-cause mortality 0.28; 0.23-0.34; P Conclusion Dipeptidyl inhibitor than did among after AKI. Therefore, prospective study CKD transitions episodes is needed optimally target interventions.